E
Nektar Therapeutics NKTR
$53.30 -$1.40-2.56% NASDAQ
Recommendation
Prev Close
$54.70
Volume
576,287
Avg Vol (90D)
908,644
Market Cap
$1.11B
Dividend & Yield
--
52-Week Range
$6.48 - $66.92
P/E (TTM)
--
EPS (TTM)
-$7.94
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Bullish Biotech Stocks With Explosive Growth Trends
7/21/2025 - MarketBeat
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
12/15/2025 - PR Newswire
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11% - Here's Why
12/13/2025 - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.5% - What's Next?
12/12/2025 - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5% - Here's What Happened
12/12/2025 - MarketBeat
Nektar Therapeutics (NKTR, $51.12) Stochastic Oscillator left the oversold zone on December 11, 2025
12/12/2025 - Tickeron - Technical Analysis
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5% - Here's What Happened
12/11/2025 - Ticker Report
Nektar Therapeutics (NKTR, $57.74) price exceeded its 50-day Moving Average on December 10, 2025
12/11/2025 - Tickeron - Stocks
Nektar Therapeutics (NKTR, $57.74) entered Downtrend as Momentum indicator drops below 0 level on Dec 10, 2025
12/11/2025 - Tickeron - Stocks
Nektar Therapeutics (NKTR, $58.78) price moved above its 50-day Moving Average on December 09, 2025
12/10/2025 - Tickeron - Stocks
Nektar Therapeutics (NKTR, $58.78) Stochastic Oscillator left the oversold zone on December 09, 2025
12/10/2025 - Tickeron - Stocks
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy
12/8/2025 - Zacks Investment Research
Nektar Therapeutics $NKTR Shares Sold by 22NW LP
12/8/2025 - MarketBeat
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/6/2025 - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/5/2025 - PR Newswire
Nektar Therapeutics (NKTR, $57.69) Stochastic Oscillator left the oversold zone on December 04, 2025
12/5/2025 - Tickeron - Stocks
Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR
12/5/2025 - MarketBeat
Nektar Therapeutics (NKTR, $57.13) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 3, 2025
12/5/2025 - Tickeron - Technical Analysis
Nektar Therapeutics (NKTR, $54.85) entered Downtrend as Momentum indicator drops below 0 level on Dec 02, 2025
12/3/2025 - Tickeron - Stocks
Nektar Therapeutics (NKTR, $54.85) price exceeded its 50-day Moving Average on December 02, 2025
12/3/2025 - Tickeron - Stocks
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5% - What's Next?
12/2/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Lexeo Therapeutics, Inc. (LXEO)
12/2/2025 - TipRanks Financial Blog
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5% - What's Next?
12/1/2025 - Ticker Report
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
12/1/2025 - Zacks Investment Research
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
6/30/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$62.60M
EBITDA (TTM)
-$135.20M
EBIT (TTM)
-$136.36M
Net Income (TTM)
-$120.74M
Balance Sheet
Total Assets (Q)
$301.35M
Total Debt (Q)
$167.08M
Total Liabilities (Q)
$216.26M
Book Value Per Share (Q)
$4.33
Cash Flow
Cash from Operations (TTM)
-$189.74M
Cash from Investing (TTM)
$58.65M
Cash from Financing (TTM)
$141.98M
Net Change in Cash (TTM)
$10.92M
Filings
Filing Date
Friday, November 7, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
2.92
7-Day Total Return
-7.61%
30-Day Total Return
-17.91%
60-Day Total Return
-3.34%
90-Day Total Return
145.06%
Year to Date Total Return
269.75%
1-Year Total Return
251.82%
2-Year Total Return
612.23%
3-Year Total Return
28.28%
5-Year Total Return
-79.86%
52-week Low
Apr 09, 2025 - $6.48
52-week High
Oct 31, 2025 - $66.92
Valuation
Market Cap
$1.11B - Small Cap
Enterprise Value
$1.01B
Price/Sales (TTM)
16.56
Price/Book (Q)
12.63
Dividends and Shares
Shares Outstanding
18.95
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.nektar.com
Phone Number
415 482 5300
Address
455 Mission Bay Boulevard South
San Francisco, CA 94158
Country
United States
Year Founded
1990
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States... more
NASDAQ 12/15/2025 4:00PM Eastern Quotes delayed